These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35182542)

  • 1. Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation.
    Di Battista V; Hey-Hawkins E
    J Pharm Sci; 2022 May; 111(5):1262-1279. PubMed ID: 35182542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.
    Haddad F; Sawalha M; Khawaja Y; Najjar A; Karaman R
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295587
    [No Abstract]   [Full Text] [Related]  

  • 3. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.
    Di Stefano A; Sozio P; Cerasa LS; Iannitelli A
    Curr Pharm Des; 2011; 17(32):3482-93. PubMed ID: 22074421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
    Paul R; Borah A
    Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in prodrug design for Parkinson's disease.
    Cacciatore I; Ciulla M; Marinelli L; Eusepi P; Di Stefano A
    Expert Opin Drug Discov; 2018 Apr; 13(4):295-305. PubMed ID: 29361853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
    Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
    CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M; Petzer JP; Viljoen F; Petzer A
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
    Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
    Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
    Xie CL; Zhang YY; Wang XD; Chen J; Chen YH; Pa JL; Lin SY; Lin HZ; Wang WW
    Neurol Sci; 2015 Aug; 36(8):1319-29. PubMed ID: 25981231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting levodopa effects in Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 2000 Jun; 54(3):95-101. PubMed ID: 10925733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
    Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B
    Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease.
    Morales V; McConnell J; Pérez-Garnes M; Almendro N; Sanz R; García-Muñoz RA
    J Mater Chem B; 2021 May; 9(20):4178-4189. PubMed ID: 33989370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.